UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G/A

(Amendment No. 1)

Under the Securities Exchange Act of 1934

Sarepta Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

803607100

(CUSIP Number)

December 31, 2014

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 $\boxtimes \qquad \text{Rule 13d-1(b)}$

 \boxtimes Rule 13d-1(c)

 $\square \qquad \text{Rule 13d-1(d)}$

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

CUSIP No. 803607100	13G/A	Page 2 of 7 Pages
---------------------	-------	-------------------

1.		names of reporting persons i.r.s. identification no. of above persons (entities only)		
	Perceptive	Perceptive Advisors LLC		
2.	check the appropriate box if a group*			(a) □ (b) □
3.	sec use only			, , , , , , , , , , , , , , , , ,
4.	citizenship or place of organization Delaware, United States of America			
	number of shares 5. sole voting power		0	
	beneficially owned by 6. shared voting power		2,812,352.00	
r	each reporting 7. sole dispositive power		0	
	person with:		shared dispositive power	2,812,352.00
9.	aggregate amount beneficially owned by each reporting person		2,812,352.00	
10.	check box if the aggregate amount in row (9) excludes certain shares (See Instructions)			
11.	percent of class represented by amount in row (9)		6.81%	
12.	type of reporting person (See Instructions)		IA	

CUSIP No. 803607100	13G/A	Page 3 of 7 Pages
---------------------	-------	-------------------

13.	i.r.s. identif	names of reporting persons i.r.s. identification no. of above persons (entities only) Joseph Edelman				
14.	check the appropriate box if a group*			(a) □ (b) □		
15.	sec use only					
16.	citizenship or place of organization United States of America					
	number of shares 17. sole voting power		0			
	beneficially owned by 18. shared voting power		2,812,352.00			
	each reporting 19. sole dispositive power		0			
person with:		20.	shared dispositive power	2,812,352.00		
21.	aggregate amount beneficially owned by each reporting person		2,812,352.00			
22.	check box if the aggregate amount in row (9) excludes certain shares (See Instructions)					
23.	percent of class represented by amount in row (9)		6.81%			
24.	type of reporting person (See Instructions)		IN			

(b) Item 2.	Name of Issuer: Address of Issuer's Principal Executiv Name of Person Filing: Address of Principal Business Office	This Sch Commo are bene	215 Can nedule 13G/A (the "Scho n Stock (as defined belo eficially owned by Perco	w) of Sarepta Therapeutics, Inc. (the "Issuer") which	
(b) Item 2.	Address of Issuer's Principal Executiv Name of Person Filing:	ve Offices: This Sch Common are bene	215 Can nedule 13G/A (the "Scho n Stock (as defined belo eficially owned by Perco	nbridge, MA 02142 edule") is being filed with respect to shares of w) of Sarepta Therapeutics, Inc. (the "Issuer") which	
Item 2.	Name of Person Filing:	This Sch Commo are bene	Can nedule 13G/A (the "Scho n Stock (as defined belo eficially owned by Perco	nbridge, MA 02142 edule") is being filed with respect to shares of w) of Sarepta Therapeutics, Inc. (the "Issuer") which	
	C	Common are bene	n Stock (as defined belo eficially owned by Perco	w) of Sarepta Therapeutics, Inc. (the "Issuer") which	
(a) 1	C	Common are bene	n Stock (as defined belo eficially owned by Perco	w) of Sarepta Therapeutics, Inc. (the "Issuer") which	
	Address of Principal Business Office		in the source of	This Schedule 13G/A (the "Schedule") is being filed with respect to shares of Common Stock (as defined below) of Sarepta Therapeutics, Inc. (the "Issuer") which are beneficially owned by Perceptive Advisors LLC and Joseph Edelman (together, the "Reporting Persons"). See Item 4 below.	
(b)		or, if none, Residence:		499 Park Avenue, 25 th Floor New York, NY 10022	
(c) (Citizenship:		Perceptive Advisors LLC is a Delaware limited liability company and Joseph Edelman is a United States Citizen.		
(d)	Title of Class of Securities:		n Stock		
(e) (CUSIP Number:	8036071	.00		
Item 3.	If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:				
	Broker or dealer registered under section 15 of the Act (15 U.S.C. 780).				
		3(a)(6) of the Act (15 U.S.			
	 Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). 				
	\square Investment company registered under section 8 of the investment Company Act of 1940 (15 U.S.C 80a-8). \square An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);				
	An investment adviser in accordance with $(240.13d-1(6)(1)(1)(1))$, An employee benefit plan or endowment fund in accordance with $(240.13d-1(b)(1)(1)(1))(F)$;				
(g)	A parent holding company	y or control person in accor	rdance with § 240.13d-1	(b)(1)(ii)(G);	
(h)				rance Act (12 U.S.C. 1813);	
(i)			an investment company	y under section 3(c)(14) of the Investment Company Act	
(j) I	of 1940 (15 U.S.C. 80a-3); □ Group, in accordance with				

CUSIP No. 803607100	13G/A	Page 5 of 7 Pages	

Item 4. Ownership.

(iv)

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a)	Amount ber	neficially owned:		nares of Common Stock which are held by an investment c serves as the investment manager. Mr. Edelman is the
(b)	Percent of c	lass:	The beneficial ownership percentages are based on th Issuer, as disclosed on the Issuer's Form 10-Q filed with	e 41,309,944 outstanding shares of Common Stock of the a the SEC on November 6, 2014.
(c)	Number of shares as to which has:		the person	
	(i)	Sole power to vo	te or to direct the vote:	0
	(ii)	Shared power to	vote or to direct the vote:	2,812,352
	(iii)	Sole power to dis	spose or to direct the disposition of:	0

2,812,352

Item 5 Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: \Box .

Item 6 Ownership of More Than Five Percent on Behalf of Another Person

Shared power to dispose or to direct the disposition of:

The Fund and the Account described in Item 4 have the right to receive or the power to direct the receipt of dividends from, or the proceeds from, the sale of the securities held in its account. Filing of this statement by the Reporting Persons shall not be deemed an admission that they beneficially own the securities reported herein. The Reporting Persons expressly disclaim beneficial ownership of all securities reported herein.

Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

CUSIP No. 803607100	13G/A	Page 6 of 7 Pages
---------------------	-------	-------------------

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10.	Certification
	The following certification shall be included if the statement is filed pursuant to §240.13d-1(b) with respect to Perceptive Advisors LLC:
(a)	By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
	The following certification shall be included if the statement is filed pursuant to §240.13d-1(c) with respect to Joseph Edelman:
(b)	By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. 803607100	13G/A	Page 7 of 7 Pages
---------------------	-------	-------------------

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 17, 2015 Date

PERCEPTIVE ADVISORS LLC

<u>/s/ Joseph Edelman</u> Signature

Joseph Edelman/Managing Member Name/Title

February 17, 2015 Date

<u>/s/ Joseph Edelman</u> Signature

Joseph Edelman Name/Title

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties for whom copies are to be sent.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)